2-TIRZ
Tirzepatide · 30mg · Lyophilised Powder
A new frontier in
metabolic science.
Tirzepatide is a novel once-weekly injectable peptide that acts as a dual agonist at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism represents a significant evolution beyond single-receptor agonism, offering researchers a uniquely powerful tool to investigate the interplay between incretin pathways, insulin sensitivity, and energy homeostasis simultaneously.
In landmark clinical investigations, tirzepatide has demonstrated reductions in body weight and HbA1c exceeding those observed with any previously approved agent in its class. Preclinical models have shown it modulates adipogenesis, reduces hepatic lipid accumulation, and influences central appetite-regulation circuits. Velthra's 2-TIRZ is provided as a high-purity lyophilised preparation, formulated for research teams investigating metabolic disease, adipose biology, and the pharmacodynamics of dual incretin receptor engagement.
Dual Incretin Agonism
Simultaneous activation of GIP and GLP-1 receptors. Enables research into additive or synergistic effects on insulin secretion, glucagon suppression, and gastric emptying.
Adipose Tissue Remodelling
Preclinical data supports investigation into visceral fat reduction, lipolysis regulation, and changes in adipokine expression profiles in obese animal models.
Hepatic & Glycaemic Pathways
Studied for effects on hepatic glucose output, non-alcoholic fatty liver disease models, and insulin resistance biomarkers in metabolic syndrome contexts.
